Consistent with this notion, intraperitoneal administration of the PKC inhibitor Ro-32-0432 reduces pro-inflammatory cytokines such as IL-1β which activates Cx43 S368 phosphorylation, as well as reduces biomarkers of heart failure in the EAM model (186). This evidence concerns the gene GJA1 and heart failure.